Valuation: Cybin Inc.

Market Cap 1.4B 995M 869M 817M 746M 95.1B 1.4B 9.81B 3.78B 48.56B 3.74B 3.65B 157B P/E 2027 *
-5.17x
P/E 2028 * -6.27x
Enterprise Value 923M 656M 574M 539M 492M 62.74B 923M 6.47B 2.5B 32.04B 2.46B 2.41B 103B EV / Sales 2027 *
-
EV / Sales 2028 * 74.8x
Free-Float
86.09%
Yield 2027 *
-
Yield 2028 * -
1 day+0.77%
1 week+4.19%
Current month+16.24%
1 month+4.99%
3 months+181.86%
6 months+201.10%
Current year+67.11%
1 week 12.1
Extreme 12.095
15.15
1 month 11.26
Extreme 11.255
15.15
Current year 3.76
Extreme 3.76
15.15
1 year 3.76
Extreme 3.76
15.15
3 years 3.76
Extreme 3.76
28.04
5 years 3.76
Extreme 3.76
92.34
10 years 3.76
Extreme 3.76
128.44
Manager TitleAgeSince
Chief Operating Officer 37 13/10/2016
Chief Executive Officer 53 03/08/2026
Chief Executive Officer 51 02/09/2025
Director TitleAgeSince
Chairman 51 05/11/2020
Director/Board Member 37 13/10/2016
Director/Board Member 65 05/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
17/09/26 Other

Chief Executive Officer

1,426,902 2.3020%
15/09/26 Buy

General Counsel

2,000 0.0032%
15/09/26 Buy

General Counsel

1,000 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
+0.73%+4.19%+125.95%-34.59% 998M
-0.07%+5.66%+54.34%+113.69% 74.33B
-1.45%-0.40%+35.52%+79.18% 62.26B
-0.66%+7.14%+39.36%+29.20% 27.72B
-1.26%-0.14%-17.43%+357.59% 26.42B
+1.97%+3.80%+1.66%-4.09% 24.62B
+0.84%+6.00%+25.53%-9.89% 20.72B
+0.87%-2.52%+151.81%+328.17% 15.01B
+2.51%+2.99%+48.05%+172.81% 14.18B
+0.50%-1.70%-10.45%+814.71% 13.48B
Average +0.43%+0.70%+45.44%+184.68% 27.97B
Weighted average by Cap. -0.07%+2.09%+37.16%+148.92%

Financials

2027 *2028 *
Net sales - 11.07M 7.87M 6.88M 6.46M 5.9M 752M 11.07M 77.56M 29.93M 384M 29.55M 28.9M 1.24B
Net income -261M -185M -162M -152M -139M -17.72B -261M -1.83B -705M -9.05B -696M -681M -29.17B -262M -186M -163M -153M -139M -17.78B -262M -1.83B -707M -9.08B -698M -683M -29.27B
Net Debt -476M -338M -296M -278M -254M -32.36B -476M -3.34B -1.29B -16.52B -1.27B -1.24B -53.27B -571M -406M -355M -333M -304M -38.81B -571M -4B -1.54B -19.82B -1.52B -1.49B -63.89B
Logo Cybin Inc.
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Employees
100
Date Price Change Volume
22/09/26 $13.66 0.00% 1,199,441
21/09/26 $13.66 +10.43% 2,873,444
18/09/26 $12.37 -11.77% 5,666,926
17/09/26 $14.02 +4.08% 3,344,325
16/09/26 $13.47 +2.67% 928,170
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
19.15CAD
Average target price
56.58CAD
Spread / Average Target
+195.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HELP Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!